EcoR1 Capital LLC lowered its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 72.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 185,472 shares of the biotechnology company’s stock after selling 487,628 shares during the period. Aclaris Therapeutics comprises approximately 0.9% of EcoR1 Capital LLC’s holdings, making the stock its 19th largest position. EcoR1 Capital LLC owned 0.69% of Aclaris Therapeutics worth $5,030,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Franklin Resources Inc. boosted its holdings in Aclaris Therapeutics by 55.4% in the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock worth $53,030,000 after buying an additional 697,104 shares during the period. Rosenblum Silverman Sutton S F Inc. CA boosted its holdings in Aclaris Therapeutics by 17.3% in the 2nd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock worth $1,041,000 after buying an additional 5,650 shares during the period. American International Group Inc. boosted its holdings in Aclaris Therapeutics by 31.3% in the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock worth $203,000 after buying an additional 1,623 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in Aclaris Therapeutics by 6.6% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock worth $1,311,000 after buying an additional 2,736 shares during the period. Finally, Westfield Capital Management Co. LP boosted its holdings in Aclaris Therapeutics by 79.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock worth $33,880,000 after buying an additional 553,752 shares during the period. 95.85% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Aclaris Therapeutics, Inc. (ACRS) Position Trimmed by EcoR1 Capital LLC” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/aclaris-therapeutics-inc-acrs-position-trimmed-by-ecor1-capital-llc/1615673.html.

Several research analysts recently weighed in on ACRS shares. ValuEngine raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a report on Friday, June 16th. They issued an “overweight” rating and a $50.00 target price for the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, June 28th. Guggenheim reaffirmed a “buy” rating and issued a $40.00 target price on shares of Aclaris Therapeutics in a report on Tuesday, July 4th. Finally, BidaskClub raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $41.25.

Shares of Aclaris Therapeutics, Inc. (ACRS) traded up 1.47% during mid-day trading on Friday, reaching $27.61. 305,732 shares of the company’s stock traded hands. Aclaris Therapeutics, Inc. has a 12-month low of $20.15 and a 12-month high of $33.25. The company’s 50 day moving average is $25.92 and its 200 day moving average is $27.19. The company’s market cap is $738.18 million.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. On average, analysts predict that Aclaris Therapeutics, Inc. will post ($3.10) EPS for the current fiscal year.

In related news, Director Andrew N. Schiff bought 108,601 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were acquired at an average price of $23.02 per share, for a total transaction of $2,499,995.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.30% of the stock is owned by company insiders.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.